B
Bakul Pharma Pvt., Ltd.
• Bakul Pharma Private Limited • Bakul Finechem Research Centre. Home | Company Information | Products | Major Reaction Capabilities | Facilities | Careers ...
Country/Area ：India
Company Email ：hiren.shah@bakulpharma.com
Industry ：Vehicles & TransportationFood and AgricultureChemicals MaterialsManufacturing GeneralManufacturing
Company address ：16/2, STERLING CENTER, 4TH FLOOR,, DR. A B.ROAD, WORLI
Company website ：*****
Company phone ：+91 2224934638
Established ：1997
Company Revenue ：$4,870,000
Number of employees ：11-50
SIC Code ：28283
NAICS Code ：32325
Main Products ：Research and DevelopmentIntermediates and Speciality Chemicals .CSR PolicyActive Pharmaceutical Ingredients (APIs) ,MilestonesManufacturingMajor Reaction Capabilities |Facilities
Business Info
CIN ：U24230MH1997PTC111089
Registered State ：Maharashtra
Registrar Of Companies ：RoC-Mumbai
Category ：Company limited by Shares
Sub Category ：Non-govt company
Company Class ：Private
Company Status ：Active
Registered Office Address ：16/2 STERLING CENTRE4TH FLOOR DR A B ROAD WORLI MUMBAI MH IN 400018
Authorized Cap ：1000000.00
Paidup Capital ：990000.00
Web Summary
Q1: What is the name of the company's founder and Managing Director?
A1: Mr. Yogin R. Majmudar is the founder and Managing Director of the Bakul group of companies.
Q2: Where are the manufacturing facilities located?
A2: The API and intermediate manufacturing facilities are located in the Western Indian states of Gujarat and Maharashtra, specifically in Ankleshwar, Gujarat, and Patalganga, Maharashtra.
Q3: What is the name of the company's research centre?
A3: Bakul Finechem Research Centre, located in Mumbai, was established in 1975, with the goal of developing efficient synthetic routes for manufacturing APIs and intermediates.
Q4: What is the company's vision statement?
A4: The company's vision statement is to fulfill the commitment to deliver sophisticated Bulk actives and Intermediates for global healthcare needs in a costeffective manner while minimizing its impact on the environment.
Q5: What is the company's CSR policy?
A5: The company defines its CSR policy as follows: "We will use our CSR funds for the advancement of mankind, particularly the people of India by investing in research and development, education, healthcare for the needy, environmental preservation and other humanitarian+social+charitable activities which benefit not only mankind, but also the planet as well for generations to come."
Q6: What is the company's manufacturing capacity?
A6: The production facilities are capable of performing a large number of synthetic conversions including those requiring cryogenic conditions. The total workforce is 300+, and they undergo regular refresher training programs in GMP, Safety, and environmental protection.
Q7: What is the company's commitment to environmental preservation?
A7: All manufacturing facilities have elaborate effluent treatment facilities, and the company strives to set aside at least 10% of the area in its manufacturing facilities for the plantation of trees to counterbalance the carbon emissions that arise from its facilities.
Q8: What is the company's US FDA approval status?
A8: Both manufacturing facilities are now US FDA approved, with an Electronic Inspection Report (EIR) received in 2025.
A1: Mr. Yogin R. Majmudar is the founder and Managing Director of the Bakul group of companies.
Q2: Where are the manufacturing facilities located?
A2: The API and intermediate manufacturing facilities are located in the Western Indian states of Gujarat and Maharashtra, specifically in Ankleshwar, Gujarat, and Patalganga, Maharashtra.
Q3: What is the name of the company's research centre?
A3: Bakul Finechem Research Centre, located in Mumbai, was established in 1975, with the goal of developing efficient synthetic routes for manufacturing APIs and intermediates.
Q4: What is the company's vision statement?
A4: The company's vision statement is to fulfill the commitment to deliver sophisticated Bulk actives and Intermediates for global healthcare needs in a costeffective manner while minimizing its impact on the environment.
Q5: What is the company's CSR policy?
A5: The company defines its CSR policy as follows: "We will use our CSR funds for the advancement of mankind, particularly the people of India by investing in research and development, education, healthcare for the needy, environmental preservation and other humanitarian+social+charitable activities which benefit not only mankind, but also the planet as well for generations to come."
Q6: What is the company's manufacturing capacity?
A6: The production facilities are capable of performing a large number of synthetic conversions including those requiring cryogenic conditions. The total workforce is 300+, and they undergo regular refresher training programs in GMP, Safety, and environmental protection.
Q7: What is the company's commitment to environmental preservation?
A7: All manufacturing facilities have elaborate effluent treatment facilities, and the company strives to set aside at least 10% of the area in its manufacturing facilities for the plantation of trees to counterbalance the carbon emissions that arise from its facilities.
Q8: What is the company's US FDA approval status?
A8: Both manufacturing facilities are now US FDA approved, with an Electronic Inspection Report (EIR) received in 2025.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
